Phathom Pharmaceuticals Inc (NASDAQ:PHAT) shares traded -1.45% lower at $7.50 on Wall Street last session.
PHAT stock price is now -37.14% away from the 50-day moving average and -38.14% away from the 200-day moving average. The market capitalization of the company currently stands at $512.83M.
With the price target of $24, Stifel recently initiated with Buy rating for Phathom Pharmaceuticals Inc (NASDAQ: PHAT). On January 05, 2024, Needham reiterated its ‘Buy’ rating on the stock by increasing its target price from $23 to quote $26, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, Nabulsi Azmi, Chief Operating Officer sold 1,118 shares of the company’s stock on Dec 19 ’24. The stock was sold for $8,944 at an average price of $8.00. Upon completion of the transaction, the Chief Operating Officer now directly owns 239,303 shares in the company, valued at $1.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19 ’24, CFO and CBO Henderson Molly sold 1,291 shares of the business’s stock. A total of $10,328 was realized by selling the stock at an average price of $8.00. This leaves the insider owning 98,156 shares of the company worth $0.74 million. A total of 49.01% of the company’s stock is owned by insiders.
During the past 12 months, Phathom Pharmaceuticals Inc has had a low of $6.07 and a high of $19.71. The fifty day moving average price for PHAT is $12.0878 and a two-hundred day moving average price translates $12.127725 for the stock.
The latest earnings results from Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was released for 2024-09-30.
